Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity turns positive
Q1 FY2026 total equity was $4.96M, compared with -$161.11K a year earlier.
Context
- Total equity amounted to 85.7% of total assets at the end of Q1 FY2026, up 52.9 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +3180.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 5.91M USD
- Year-over-year change
- +819.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.91M | +819.6% |
| FY2024 | 2024-12-31 | 643.04K | -81.3% |
| FY2023 | 2023-12-31 | 3.44M | +466.8% |
| FY2022 | 2022-12-31 | (937.28K) | -1027.5% |
| FY2021 | 2021-12-31 | (83.13K) | — |
Total Equity vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 total equity of $4.96M is the 5th highest of the 6 companies compared; the peer median is $19.62M.
- Its year-over-year change of +3180.1% is the highest of 6, against a peer median of +10.1%.
- Total equity amounts to 85.7% of total assets for TELO, versus a peer median of 88.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $264.74M | +10.1% | -19.3% | 81.1% | |
| Mar 2026 | $59.49M | +462.4% | -3.6% | 94.3% | |
| Mar 2026 | $19.62M | -33.9% | -26.9% | 76.0% | |
| Mar 2026 | $17.58M | +135.5% | +58.6% | 88.8% | |
| Mar 2026 | $4.96M | +3180.1% | — | 85.7% | |
| Mar 2026 | -$265.65M | -29.0% | — | 202.1% | |
| Peer median (excluding TELO) | $19.62M | +10.1% | -11.5% | 88.8% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.